STAT3 and cancer: Considering that we have previously shown that MDA-9/Syntenin can activate STAT-3 in cancer cells [33], we postulate that lack of mda-9/syntenin in our mda-9−/− mice may abrogate STAT-3-mediated IL-17 production.